Showing 6061-6070 of 7313 results for "".
- ACS Study: Skin Creams Aren’t What We Thought They Werehttps://practicaldermatology.com/news/acs-study-skin-creams-arent-what-we-thought-they-were/2460136/Researchers report the first direct glimpse of how a skin cream or lotion is structured on the molecular scale, and it’s not quite what they expected. They presented their results at the American Chemical Society (ACS) Fall 2019 National Meeting & Exposition in San Diego.
- Lilly’s Oral JAK Inhibitor Plus Steroids Improves AD Symptomshttps://practicaldermatology.com/news/lillys-oral-jak-inhibitor-plus-steroids-improves-ad-symptoms/2460134/Adding the oral JAK inhibitor baricitinib to standard-of-care topical corticosteroids significantly improved atopic dermatitis disease severity, measured by the validated Investigator's Global Assessment for AD (vIGA) score of "clear or almost clear" skin (vIGA 0, 1), the primary en
- ASDS 2018 Survey: Skin Cancer Treatments and Cosmetic Procedures are on the Risehttps://practicaldermatology.com/news/asds-2018-survey-skin-cancer-treatments-and-cosmetic-procedures-are-on-the-rise/2460133/American Society for Dermatologic Surgery (ASDS) member dermatologists performed more than 12.5 million medical and cosmetic procedures in 2018 – 7.5 percent more than 2017 and a 60 percent increase since 2012, according to the 2018 ASDS
- Cassiopea Submits NDA for New Acne Treatmenthttps://practicaldermatology.com/news/cassiopea-submits-nda-for-new-acne-treatment/2460131/Cassiopea SpA submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for clascoterone cream 1% for the treatment of acne. Clascoterone cream 1% is under investigation as a first-in-class topical androgen receptor inhibitor for th
- Soliton Treats First Patients in Cellulite Trialhttps://practicaldermatology.com/news/soliton-treats-first-patients-in-cellulite-trial/2460124/The first patients in Soliton’s cellulite trial have been treated, the Company reports. "Patient treatments have now begun at the Chicago site,” says Dr. Chris Capelli, President, CEO and co-founder of Soliton, in a ne
- Foamix Submits NDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosaceahttps://practicaldermatology.com/news/foamix-submits-nda-for-fmx103-for-the-treatment-of-moderate-to-severe-papulopustular-rosacea/2460117/Foamix Pharmaceuticals Ltd. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for FMX103 for the treatment of moderate-to-severe papulopustular rosacea in patients 18 years of age and older
- Nebraska Gets “SUNucated”https://practicaldermatology.com/news/nebraska-gets-sunucated/2460116/Nebraska is the latest state to recommend that children be allowed to possess and use sunscreen without a doctor’s note at school and at school-sponsored events. “I am thrilled that Nebraska is stepping up to the plate with commonsense information that will now be con
- Has Cellulite Finally Met its Match with BTL’s Emtone?https://practicaldermatology.com/news/has-cellulite-finally-met-its-match-with-btls-emtone/2460114/Drumroll please…BTL is launching Emtone, a device that targets cellulite via thermal monopolar radiofrequency and mechanical targeted pressure energy simultaneously. This combination results in increased production of collagen and elastin&
- New AAD, NPF Guidelines Address Psoriasis Phototherapyhttps://practicaldermatology.com/news/new-aad-npf-guidelines-address-psoriasis-phototherapy/2460109/New guidelines from the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) take on psoriasis phototherapy. The
- Summer AAD News: Hyperhidrosis Updatehttps://practicaldermatology.com/news/summer-aad-news-hyperhidrosis-update/2460106/At least 15 million people in the U.S. experience diminished quality of life due to hyperhidrosis, yet half of people with the condition delay treatment for 10 years or more, according to information presented at the 2019 American Academy of Dermatology Summer Meeting in New York City.